IMS Health buys trial-enrollment software startup

Health information heavyweight IMS Health has gobbled up DecisionView, a San Francisco-based provider of web-based software that analyzes patient enrollment in clinical trials via an acquisition. Venture-backed DecisionView--which has a customer roster that includes drug giants such as Merck ($MRK), GlaxoSmithKline ($GSK) and Roche ($RHHBY)--provides a tool for benchmarking enrollment trends by trial type and geography. Patient recruitment has been one of the biggest challenges to getting studies done on time, in an industry where every day a program is delayed can mean millions of dollars in lost opportunity. IMS, based in Danbury, CT, and DecisionView didn't reveal financial terms of the deal. Release | Article

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.